Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 2, 2002, Pages 141-147

  Mathur, Surekha ^a   Devaraj, Sridevi ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; STATINE DERIVATIVE;

ATHEROGENESIS; ATHEROSCLEROSIS; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS;

EID: 0036189245     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200203000-00003     Document Type: Review

References (96)

1. Nontraditional cardiovascular risk factors
2. Dyslipidemia and renal disease: Pathogenesis and clinical consequences
3. Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients
4. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease
5. Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia?
6. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
7. Lipid abnormalities in end-stage renal disease
8. Atherogenicity of triglyceride rich lipoproteins
9. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis
10. Detection, quantitation and characterisation of potentially atherogenic TRL
11. Accumulation of lipoprotein remnants in patients with chronic renal failure
12. Postprandial lipoprotein metabolism and atherosclerosis
13. RLP-cholesterol levels in patients with dysbetalipoproteinemia and CAD
14. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease
15. RLP and restenosis of coronary arteries after PTCA
16. Association of plasma TG-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden death
17. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels
18. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis
19. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis
20. An increase of serum remnant-like particles in non-insulin-dependent diabetic patients with microalbuminuria
21. Pathophysiology of triglyceride-rich lipoproteins
22. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
23. Intermediate density lipoproteins as an independent risk factor for aortic atherosclerosis in hemodialysis patients
24. Progression of renal failure: Role of apolipoprotein B containing lipoproteins
25. Low density lipoprotein subfraction profiles in chronic renal failure
26. Characterization of low-density lipoprotein subclasses: Methodologic approaches and clinical relevance
27. Low density lipoprotein particle size and coronary artery disease
28. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
29. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
30. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
31. Lipoprotein subspecies and risk of coronary disease
32. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
33. Lipoproteins and apolipoproteins during the progression of chronic renal disease
34. Premature cardiovascular disease in chronic renal failure
35. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications
36. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study
37. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
38. The low molecular weight apo(a) phenotype is an independent predictor for coronary artey disease in hemodialysis patients: A prospective follow-up
39. Lipoprotein (a) concentration and apolipoprotein (a) size: A synergistic role in advanced atherosclerosis?
40. Increased serum lipoprotein (a) levels in patients with early renal failure
41. Lipoprotein(a) in renal disease
42. Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies
43. Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes
44. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients
45. Oxidation of low-density lipoproteins from patients with renal failure or renal transplants
46. Low-density (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy
47. LDL enhances monocyte adhesion to endothelial cells in vitro
48. Advanced glycosylation end products in patients with diabetic nephropathy
49. Reactive carbonyl compounds related uremic toxicity ('carbonyl stress')
50. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications
51. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship?
52. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
53. Additive impacts of diabetes and renal failure on carotid atherosclerosis
54. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
55. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on RLP levels in patients with combined hyperlipidemia
56. RLP cholesterol concentration and progression of coronary and vein graft atherosclerosis is response to gemfibrozil treatment
57. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
58. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD
59. An overview of haemodialysis and oxidant stress
60. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
61. Oxidative stress in hemodialysis
62. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure
63. 2-isoprostanes in patients on long-term dialysis
64. Manifestations of oxidant stress in uremia
65. Evidence for oxidative stress during in-vitro dialysis
66. Increased lipid peroxidation in patients on maintenance hemodialysis
67. Influence of dialysis on plasma lipid peroxidation products and antioxidant levels
68. Evaluation of oxidant stress in chronic hemodialysis patients: Use of different parameters
69. Susceptibility of VLDL to oxidation in patients on regular hemodialysis
70. Increased susceptibility of LDL to in-vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration
71. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?
72. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis
73. Oxidation of low-density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls
74. Oxidation of low-density lipoprotein in patients on regular haemodialysis
75. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
76. Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients
77. Analysis of 7-ketocholesterol in low density lipoprotein and fatty acid composition in erythrocyte membranes of patients on maintenance hemodialysis and healthy controls
78. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients
79. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients
80. 2-isoprostanes: Sensitive and specific non-invasive indices of lipid peroxidation in vivo
81. The generation and actions of isoprostanes
82. Isoprostanes-potential markers of oxidant stress in atherothrombotic disease
83. 2-alpha and platelet activation in diabetes mellitus: Effect of improved metabolic control and vitamin E supplementation
84. 2 alpha levels are elevated in individuals with NIDDM
85. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy
86. Effect of α-tocopherol on in-vitro and in-vivo metabolism of low-density lipoproteins in haemodialysis patients
87. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): Randomized placebo-controlled trial
88. Vitamin E, lipid profile, and peroxidation in hemodialysis patients
89. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients
90. Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer
91. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes
92. Alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals
93. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients
94. Failure to demonstrate a major anti-inflammatory effect with alpha tocopherol supplementation (400 IU/day) in normal subjects